Mr. Klausner is currently CEO of Goldilocks Therapeutics, Inc., a start-up company formed to advance nanoparticle technology developed at Memorial Sloan Kettering Cancer Center for the treatment of acute kidney injury. He had previously served as CEO and a Boardmember of Gem Pharmaceuticals (acquired by Monopar Therapeutics in 2017), and CEO and a Boardmember of Jade Therapeutics (acquired by EyeGate Pharmaceuticals in 2016).
Prior to his operating roles, Klausner spent a total of 18 years as a life sciences venture capitalist at Domain Associates and Pappas Ventures. During that time, he was involved in the investment in and subsequent nurturing of a variety of biotechnology, specialty pharmaceutical, and medical device companies. Klausner has been a board member at Santarus (IPO in 2004), X-Ceptor (acquired by Exelixis in 2004), Orexigen (IPO in 2007), and Syndax Pharmaceuticals (IPO in 2016), and a board observer at Peninsula Pharmaceuticals (acquired by Johnson & Johnson in 2005) and Cerexa (acquired by Forest Laboratories in 2007). He currently serves on the Board of Directors of Goldilocks Therapeutics, Monopar Therapeutics, and Cennerv Pharma (Singapore), as well as on Advisory Boards for Neurotez, the New York University Innovation Venture Fund, and 1st Pitch Life Science.
Klausner began his venture capital career after earning an M.B.A. at the Stanford University Graduate School of Business. Previously, Klausner had spent six years at Bio/Technology magazine (now Nature Biotechnology), where as Senior Editor he researched and prepared over 200 articles concerning scientific and business aspects of applied biology. He has also performed consulting projects for the U.S. Office of Technology Assessment, Arthur D. Little Decision Resources, and a range of pharmaceutical and biotechnology companies. His undergraduate degree in Biology is from Princeton University.